Loading...
AXIM Biotechnologies, Inc.
AXIM•PNK
Healthcare
Biotechnology
$0.007
$0.001(16.28%)
AXIM Biotechnologies, Inc. (AXIM) Financial Performance & Statements
Review AXIM Biotechnologies, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
78.29%
↑ 78.29%
Operating Income Growth
35.91%
↑ 35.91%
Net Income Growth
56.42%
↑ 56.42%
Operating Cash Flow Growth
17.02%
↑ 17.02%
Operating Margin
-2506.28%
↓ 2506.28%
Gross Margin
-370.64%
↓ 370.64%
Net Profit Margin
-4985.19%
↓ 4985.19%
ROE
37.56%
↑ 37.56%
ROIC
53.27%
↑ 53.27%
AXIM Biotechnologies, Inc. (AXIM) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for AXIM Biotechnologies, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $17479.00 | $52979.00 |
| Cost of Revenue | $115838.00 | $106013.00 | $1744.00 | $108007.00 |
| Gross Profit | -$115838.00 | -$106013.00 | $15735.00 | -$55028.00 |
| Gross Profit Ratio | $0.90 | -$1.04 | ||
| R&D Expenses | $10388.00 | $10086.00 | $4063.00 | $15495.00 |
| SG&A Expenses | $245405.00 | $304343.00 | $472984.00 | $333840.00 |
| Operating Expenses | $255793.00 | $314429.00 | $583432.00 | $349335.00 |
| Total Costs & Expenses | -$371631.00 | -$420442.00 | $585176.00 | $457342.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $97582.00 | $76039.00 | $238858.00 | $223681.00 |
| Depreciation & Amortization | $110245.00 | $106013.00 | $108129.00 | $108007.00 |
| EBITDA | -$213758.00 | -$351717.00 | -$1.92M | $39389.00 |
| EBITDA Ratio | -$110.008 | $0.74 | ||
| Operating Income | -$371631.00 | -$420442.00 | -$569441.00 | -$404360.00 |
| Operating Income Ratio | -$32.58 | -$7.63 | ||
| Other Income/Expenses (Net) | -$44953.00 | -$113326.00 | -$1.70M | $109264.00 |
| Income Before Tax | -$416584.00 | -$533768.00 | -$2.27M | -$292299.00 |
| Income Before Tax Ratio | -$129.86 | -$5.52 | ||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$404363.00 |
| Net Income | -$416584.00 | -$533768.00 | -$2.27M | -$292299.00 |
| Net Income Ratio | -$129.86 | -$5.52 | ||
| EPS | -$0.001 | -$0.002 | -$0.008 | -$0.001 |
| Diluted EPS | -$0.001 | -$0.002 | -$0.01 | -$0.001 |
| Weighted Avg Shares Outstanding | $318.90M | $302.90M | $288.91M | $261.40M |
| Weighted Avg Shares Outstanding (Diluted) | $318.90M | $302.90M | $288.91M | $261.40M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan